Related Experiment Video
Updated: Sep 7, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival
Matteo Santoni1, Fernando Sabino M Monteiro2, Francesco Massari3
1Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, Italy.
Abstract:
Statins are commonly prescribed to reduce plasma cholesterol levels and risk of cardiovascular events and mortality. Statin exposure may have cancer-preventive properties in some solid tumors, including Renal Cell Carcinoma (RCC). Emerging evidences show that statins can inhibit RCC cell growth by inducing cell cycle arrest and apoptosis in a dose- and time-dependent manner. In addition, statins inhibit the phosphorylation of AKT, mammalian target of rapamycin (mTOR), and ERK leading to reduced motility of RCC cells. Interestingly, the potential impact of concomitant statin intake has been recently evaluated in RCC patients treated by targeted therapy or immunotherapy. In this review, we illustrate the most recent data on the preclinical activity of statins in Renal Cell Carcinoma models and discuss the impact of their use on the prevention and survival of patients affected by this tumor.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cancer Survival Analysis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Drugs that Stabilize Microtubules

